
https://www.science.org/content/blog-post/novartis-no-more-neuroscience
# Novartis: No More Neuroscience (December 2011)

## 1. SUMMARY
This 2011 commentary discusses the major pharmaceutical companies exiting neuroscience drug discovery due to the field's reputation as a "graveyard" - characterized by high unmet medical needs but extreme difficulty in developing effective treatments. The article notes that GlaxoSmithKline and AstraZeneca had already withdrawn from neuroscience research, with Novartis now joining them by shutting down their brain research facility. The author reflects on their own experience in CNS drug discovery and suggests that while reduced industry participation might slow overall progress, it could create opportunities for smaller organizations to capitalize on new discoveries. The piece identifies two immediate consequences: decreased funding and research effort across the field, but potentially more room for specialized, innovative approaches from smaller players willing to pursue the high-risk, high-reward nature of neuroscience drug development.

## 2. HISTORY
Following the 2011 article, the neuroscience drug development landscape evolved significantly. Several major pharmaceutical companies did reduce their neuroscience portfolios between 2010-2015, with Pfizer, Merck, and Sanofi also scaling back CNS research during this period. However, this retreat created opportunities that the article accurately anticipated.

The subsequent decade saw notable developments: Biogen's aducanumab received controversial FDA approval for Alzheimer's in 2021 (though with limited clinical uptake and significant debate), while Eisai's lecanemab showed more promising results in 2022-2023. Multiple sclerosis treatments continued advancing with new oral therapies and B-cell targeting drugs. Gene therapies emerged for rare neurological disorders like spinal muscular atrophy (Novartis's Zolgensma, approved 2019) and inherited retinal diseases.

The biotechnology sector did fill some gaps left by large pharma exits. Companies like Sage Therapeutics developed novel antidepressants (Zulresso 2019), and smaller firms pursued psychedelic-assisted therapies, digital therapeutics, and precision medicine approaches. The field experienced increased venture capital investment post-2015, particularly in areas like neurodegeneration, pain, and psychiatric disorders.

The article's characterization of neuroscience as challenging remained accurate - high failure rates persisted, and many promising mechanisms (amyloid hypothesis for Alzheimer's, various stroke neuroprotectants) continued to disappoint in late-stage trials. However, the predicted opportunity for smaller organizations materialized, with numerous biotech companies successfully advancing neuroscience programs that larger companies had deprioritized.

## 3. PREDICTIONS
• **Prediction**: Progress may slow down due to reduced money and effort from big pharma exits.
  **Outcome**: Partially accurate. While major pharma retreat did reduce overall industry investment in the short term, progress continued through biotechnology companies, academic partnerships, and specialized CNS-focused pharmaceuticals. The pace of discovery didn't dramatically slow overall.

• **Prediction**: Smaller organizations would have opportunities to take advantage of new discoveries and "get lucky" in the space.
  **Outcome**: Largely accurate. The 2010s saw significant biotech activity in neuroscience, with companies like Acadia Pharmaceuticals, Axsome Therapeutics, and many others successfully developing and commercializing CNS drugs. Venture funding for neuro-focused biotechs increased substantially post-2015.

• **Prediction**: The rewards remain "on a high, high shelf" for those willing to try neuroscience drug discovery.
  **Outcome**: Mixed. While some notable successes occurred (gene therapies for rare diseases, new antidepressant mechanisms), the fundamental challenges remained. Most neuroscience drug candidates still failed in clinical trials, and the "high shelf" rewards proved exceptionally difficult to reach, consistent with the article's overall characterization.

## 4. INTEREST
**Score: 6**

This article captured an important industry trend at a pivotal moment and demonstrated reasonable foresight about how reduced big pharma participation might reshape neuroscience R&D, making it more historically significant than typical industry commentary.

---


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20111206-novartis-no-more-neuroscience.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_